Case report demonstrates visual dysfunction linked to semaglutide escalation in a man with obesity, suggesting clinical vigilance is needed.
Key Points
To report a case of atypical retrobulbar optic neuropathy following semaglutide dose escalation and evaluate its implications for safety monitoring.
Case report of a man in his early 30s with class III obesity and prediabetes who developed visual dysfunction after semaglutide escalation to 1 mg/week.
Evaluation included visual field tests, optical coherence tomography, and neuroimaging to assess visual function.
Semaglutide was discontinued immediately, and follow-up monitoring tracked visual stability.
Developed acute, painless, asymmetric bilateral visual dysfunction four weeks post-semaglutide escalation.
Evaluation showed retrobulbar optic neuropathy with unusual visual field defects; preserved optic disc appearance and altered visual evoked potentials confirmed severity.
Visual function remained stable upon follow-up, with adaptation to a persistent left central scotoma and no further deterioration.
Cite This Study
Channabasappa et al. (2026) studied this question.